Skip to content
OpenCapital
Get started

Abbott ABT Established Pharmaceuticals — Operating Earnings

Other segment segments

Medical Devices
$1.89B+17.7%
Diagnostic Products
$335M-6.7%
Nutritional Products
$311M-21.1%

Similar metrics at other companies

Agilent Technologies logo
ALife Sciences and Diagnostics Markets — Income from operations
$161M+24.8%
Mettler-Toledo International, Inc. logo
MTDOther Operations Segment — Segment profit
$27.54M+12.5%
Labcorp Holdings logo
LHBiopharma Laboratory Services — Operating Income
$120.7M+12.9%
STERIS logo
STEOperatingSegmentAllExceptCorpandOther — Operating Income (Loss)
$229.63M+9.9%
Agilent Technologies logo
ALife Sciences and Applied Markets — Operating Income (Loss)
$233M-2.9%
STERIS logo
STESegment operating income — Segment operating income
$343.1M+7.2%

Other financials

Income statement

See full
Revenue$11.2B+7.8%
Gross profit$6.3B+6.5%
Operating income$1.3B-20.6%
Net income$1.1B-18.7%
EPS (diluted)$0.61-19.7%

Balance sheet

See full
Cash & equivalents$6.8B+4.2%
Total debt$34.0B+157%
Total equity$52.1B+6.7%
Total assets$110.43B+35.6%

Cash flow

See full
Operating cash flow$1.3B-7.2%
CapEx$399.0M-17.6%
Free cash flow$916.0M-1.8%

Valuation

See full
Market cap$154.15B-22.5%
Enterprise value$181.39B-13.1%
P/E24.6×+9.8×
P/S3.4×-1.3×

Profitability

See full
Gross margin56.3%+0.4pp
Operating margin17.1%+0.2pp
Net margin13.9%-18.0pp

Returns & leverage

See full
Return on equity12.4%-18.4pp
Debt / equity0.7×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's established pharmaceuticals — operating earnings.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Abbott's established pharmaceuticals — operating earnings?
Abbott (ABT) reported established pharmaceuticals — operating earnings of $365M in Q1 2026.
How has Abbott's established pharmaceuticals — operating earnings changed year-over-year?
Abbott's established pharmaceuticals — operating earnings increased by 22.5% year-over-year, from $298M to $365M.
What is the long-term trend for Abbott's established pharmaceuticals — operating earnings?
Over 4 years (2021 to 2025), Abbott's established pharmaceuticals — operating earnings has grown at a 9.8% compound annual growth rate (CAGR), from $889M to $1.29B.
What does established pharmaceuticals — operating earnings mean?
The profit earned from segment operations after all operating expenses are paid.
How do you interpret established pharmaceuticals — operating earnings?
An increase indicates improved profitability through higher sales or better cost control.
How does established pharmaceuticals — operating earnings compare across companies?
Comparable to 'Segment Operating Income' or 'EBIT' for business units at other healthcare companies.